Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

VICTORIA, BC, Feb. 25, 2025 /CNW/ - Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision local drug ...

(RTTNews) - GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced the completion of negotiations with the pan-Canadian Pharmaceutical Alliance or pCPA for APRETUDE for pre-exposure ...

Created by ViiV Healthcare — a specialist pharmaceutical company dedicated to HIV medicines and research that is majority-owned by GSK — the production acknowledges the stresses and micro ...

ViiV is also working with Janssen to develop a once-monthly injectable HIV combo regimen, which recently reported positive phase 3 trial results. George Underwood 9 April, 2019 ...

ViiV did not say how it acquired the priority review voucher, but last year it used the same strategy to hasten the FDA’s review of another single-tablet combination HIV therapy of Tivicay ...